GLPwatch
A Study of LY3537021 in Healthy Participants
NCT05444569 · Completed
Last updated 2026-05-28This clinical trial tests the safety of the investigational drug LY3537021 in healthy adult participants by monitoring side effects and serious reactions.
Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, double-blind basic-science study
Participants 47 people
Who can join Ages 21–60 · all sexes Healthy volunteers accepted.
Timeline Started 2022-08 · est. completion 2023-02
Where 1 site · Singapore
What this study is testing ClinicalTrials.gov NCT05444569 ↗
Description as written by the study sponsor.
The main purpose of this study is to evaluate the safety and tolerability of LY3537021 when administered in combination with glucagon-like peptide (GLP-1) receptor agonist called liraglutide in treatment-naïve healthy participants. The study will include 2 parts. The study will last up to 16 and 22 weeks for part A and B, respectively which includes a screening period of 6 weeks.
Treatments tested
- LY3537021 Drug
Administered SC.
- Liraglutide Drug
Administered SC.
- Placebo Drug
Administered SC.
| Main thing measured | Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration |
|---|---|
| Sponsor | Eli Lilly and Company |
| Conditions studied | Healthy |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05444569 ↗